Top Markets
#1 NKN NKN +150.21%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +25.76%
#5 Saakuru Saakuru +23.97%
#6 Arcblock Arcblock +17.43%
#7 Bedrock Bedrock +16.58%
#8 pippin pippin +11.91%
#9 Bless Bless +11.44%
#10 StakeStone StakeStone +10.88%
Coin of the day
NKN NKN
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Kedudukan dalam Saham #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Harga Saham
$207.15
Modal Pasaran
$366.28B
Perubahan (1 hari)
0.99%
Perubahan (1 tahun)
2.91%
Negara
US
Perdagangan AbbVie Inc. (ABBV)

Kategori

Healthcare
Hasil untuk AbbVie Inc. (ABBV)
Hasil pada Dec 2025 TTM: $61.16B
Menurut laporan kewangan terkini daripada AbbVie Inc., hasil semasa syarikat (TTM) ialah $61.16B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $56.33B peningkatan berbanding hasil pada tahun 2023 iaitu $54.32B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi AbbVie Inc. dari 2009 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $61.16B 0.00%
2025 $61.16B 8.57%
2024 $56.33B 3.71%
2023 $54.32B -6.44%
2022 $58.05B 3.30%
2021 $56.20B 22.69%
2020 $45.80B 37.69%
2019 $33.27B 1.57%
2018 $32.75B 16.08%
2017 $28.22B 10.06%
2016 $25.64B 12.16%
2015 $22.86B 14.52%
2014 $19.96B 6.23%
2013 $18.79B 2.23%
2012 $18.38B 5.37%
2011 $17.44B 11.55%
2010 $15.64B 10.02%
2009 $14.21B 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 $65.18B 6.57%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 $58.74B -3.96%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $94.19B 54.01%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 $56.15B -8.19%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $65.01B 6.30%
US